Menstrual cycle variability of ca 72-4 in healthy women
Citation
Yarcı Gursoy, A., Kiseli, M., Ozdemir, S., Şeker, R., & Caglar, G. S. (2015). Menstrual cycle variability of CA 72-4 in healthy women. Clinical Biochemistry, 48(1-2), 70–72. https://doi.org/10.1016/j.clinbiochem.2014.09.020Abstract
Objectives: CA 72-4 is not approved as a tumormarker but has been used as an adjunct marker in gynecological
practice. The study aims to evaluate the menstrual cycle variability of CA 72-4 in a population of healthy
women.
Design and methods: Forty apparently healthy regularly menstruating subjects were included in the crosssectional
study designed in the University Obstetrics and Gynecology outpatient clinic. Venous blood samples
from each participant were collected twice: first at the follicular phase (2nd–5th days of the menstrual cycle)
for FSH, estradiol, CA 125, CA 72-4 and the other at the luteal phase (21st-24th days of the menstrual cycle)
for progesterone, CA 125 and CA 72-4 levels.
Results: CA 72-4 values were similar in follicular and luteal phase of the menstrual cycle in apparently
healthy regularly menstruating subjects (1.15 U/mL (0.2–5.4) vs 1.15 U/mL (0.56–6.3); p= 0.326 respectively).
Ovulatory or smoking status did not have an effect on CA 72-4 values (p N 0.05).
Conclusion: This first clinical study about the menstrual cycle variability of CA 72-4 revealed that the menstrual
cycle does not have a significant impact on CA 72-4 values and that it can be measured at any time during
the menstrual period.